Clinical Trial Update: Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC [Phase 1, Phase 2]

View source ↗

Summary

An early-phase, biomarker-directed trial is evaluating temozolomide in combination with stenoparib for relapsed small cell lung cancer and is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Stenoparib (stenoparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING